Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Niramas Utama Tbk. (JELI) vs UBC Medical Indonesia Tbk. (LABS) Price & Performance

Niramas Utama Tbk.Trade
UBC Medical Indonesia Tbk.Trade

Price performance (Past 24H)

Key statistics

Niramas Utama Tbk. vs UBC Medical Indonesia Tbk. — how do they compare? Niramas Utama Tbk. trades at Rp1,005 (market cap 1.31T, 64.48M 24h volume), while UBC Medical Indonesia Tbk. trades at Rp148 (market cap 576.7B, 3.48M 24h volume). The key difference: Niramas Utama Tbk. is far larger — about 2.3× UBC Medical Indonesia Tbk.'s market cap, and Niramas Utama Tbk. is more actively traded (64.48M versus 3.48M). Which is the better fit depends on your goals.

JELILABS
Market Cap
1.31T576.7B
Volume
64.48M3.48M
Lot
644.81K34.82K
Turnover
65.83B522.79M
Average Price
1,020.91150.13
Value
65.83B522.79M
Indicative Equilibrium Price
1,005148
Indicative Equilibrium Volume
24.22K350

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

JELI
View details
LABS
View details

About Niramas Utama Tbk.

PT. Niramas Utama Tbk. (the Company) formerly PT Nata Sari Raya was established based on Notarial Deed No. 86 dated 22 November 1990, by Notary Samsul Hadi, S.H. The Company started its commercial operations in 1994. The parent entity and the ultimate parent entity of the Company are PT Niramas Utama International and PT Supra Sentral Investama

Read more on JELI

About UBC Medical Indonesia Tbk.

PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.

Read more on LABS